Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax
Results published of phase I trial of ABthrax to prevent, treat anthrax
August 15th, 2005
Human Genome Sciences, Inc., (HGSI) announced that results published in the current issue of Clinical Infectious Diseases demonstrate that the first investigational agent against anthrax infection to be evaluated in a clinical study since the 2001 anthrax attacks in the United States, is safe, well tolerated and achieves the blood levels predicted by relevant animal models as necessary to afford significant protection from the lethal effects of the anthrax toxin. ABthrax, a fully human monoclonal antibody to Bacillus anthracis protective antigen, was studied in a randomized, single-blind, placebo- controlled, dose-escalation phase I clinical trial in 105...
Source: Pharma Business Week (2005-08-15)
|
